查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048112

卡介苗市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、分銷通路、地區和競爭對手分類，2021-2031年

BCG Vaccines Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球卡介苗市場預計將從 2025 年的 1.4971 億美元穩步成長到 2031 年的 2.1201 億美元，複合年成長率為 5.97%。

卡介苗（BCG）是一種源自牛桿菌的減毒活病毒疫苗，主要用於新生兒結核病預防，也可用於早期膀胱癌的膀胱內免疫治療。市場穩定主要得益於結核病高發生地區嚴格執行國家免疫接種規定，以及卡介苗在腫瘤治療方案中的持續臨床應用。這些基本因素確保了可預測的供應水平，並建立了一個獨立於疫苗接種技術進步的需求基準。然而，市場擴張的主要障礙在於全球供應鏈固有的脆弱性，其特點是生產集中在少數幾家預先獲得認證的製造商手中。這種集中性使得市場容易供不應求，並使物流複雜化，尤其是在依賴不間斷供應的低收入國家。根據聯合國兒童基金會2024年的數據，全球整體對卡介苗的需求量估計約為3.3億劑，凸顯了現有生產基礎設施在維持充足的公共衛生覆蓋範圍方面面臨的巨大壓力。

市場概覽
預測期 2027-2031
市場規模：2025年 1.4971億美元
市場規模：2031年 2.1201億美元
複合年成長率：2026-2031年 5.97%
成長最快的細分市場 醫院
最大的市場 北美洲

市場促進因素

結核病在全球高發生地區的蔓延是推動市場需求成長的主要因素，而持續的疫苗採購對於有效控制疾病至關重要。隨著感染率的上升，各國醫療衛生系統面臨越來越大的壓力，需要擴大疫苗接種覆蓋範圍和治療性介入，以遏止疾病的傳播。根據世界衛生組織（世衛組織）發布的《2024年全球結核病報告》，2023年全球新增結核病病例約820萬例，創下全球監測以來的最高紀錄。這項創紀錄的病例數凸顯了建立穩健的疫苗供應鏈以實現公共衛生目標的必要性，而開發中國家的需求尤其迫切。聯合國兒童基金會的報告顯示，預計2024年卡介苗的加權平均價格為每劑0.18美元，該價格在保證價格可負擔性的同時兼顧了生產成本。同時，卡介苗免疫療法在非肌肉浸潤性膀胱癌治療中的應用日益廣泛，顯著提升了卡介苗的市場價值，並創造了一個獨立於兒童免疫接種之外的高收入細分市場。儘管卡介苗在腫瘤治療中的應用已持續展現出良好的臨床療效，但對該方案日益成長的需求加劇了現有的生產限制，導致卡介苗供不應求。臨床應用不斷擴大與有限產能之間的矛盾在近期治療中斷事件中顯露無疑。 2024 年發表於 UroToday 的一篇報導顯示，21% 的受訪患者直接受到卡介苗供不應求的影響，迫使醫療機構調整標準治療方法。這些數據表明，供不應求仍然是限制卡介苗在腫瘤領域商業性應用的一大瓶頸。

市場挑戰

限制全球卡介苗市場成長的主要挑戰在於全球供應鏈的脆弱性，這主要是由於生產過度集中在少數幾家製造商手中所造成的。這種結構性集中化造成了高風險環境，任何一家工廠停產、監管障礙或品管失誤都可能立即引發大範圍的供不應求。因此，市場難以維持嚴格的國家免疫規劃所需的可靠性，迫使採購機構只能以最低庫存運作。這種不穩定性削弱了買家的信心，並阻礙了膀胱癌免疫療法等輔助用途的供應擴張，因為在供不應求期間，兒童醫療保健的核心需求必須優先滿足。聯合國兒童基金會2024年的評估報告鮮明地揭示了這種壟斷依賴的嚴重性，該報告發現，印度一家製造商的產能約佔所有世衛組織認證供應商總產能的70%。這種不平衡的依賴關係意味著市場缺乏有效吸收供給衝擊所需的多樣性，由此導致的冗餘不足造成了嚴重的物流瓶頸，直接阻礙了市場的穩定擴張和收益的可預測性。

市場趨勢

將卡介苗 (BCG) 納入膀胱癌聯合治療是腫瘤治療方案的關鍵轉折點，尤其解決了非肌肉層浸潤性膀胱癌 (NMIBC) 的重大臨床挑戰，因為這類患者對 BCG 治療無反應。透過將膀胱內灌注 BCG 與新型免疫調節劑（例如 IL-15促效劑偶聯物）結合，製藥開發商在不放棄 BCG 基本作用的前提下，提高了根治性治療方法的療效。這種方法透過擴大疫苗在高風險患者群體中的效用，為市場注入了活力，這些患者原本可能需要接受根治性膀胱切除術。為了展示這一臨床進展，ImmunityBio 公司在 2024 年 4 月發布的新聞稿中報告稱，ANKTIVA 與 BCG 的聯合治療在對 BCG 無反應的 NMIBC 患者中實現了 62% 的完全緩解率，為持續治療效果樹立了新的標竿。同時，隨著人們對訓練免疫研究的關注度不斷提高，這種疫苗的商業性前景正從傳統的兒童結核病適應症擴展到其他領域，其對多種呼吸道病原體和神經退化性疾病的特異性保護作用也正在研究中。這一科學趨勢利用了卡介苗誘導先天免疫細胞表觀遺傳重編程的能力，從而增強宿主的廣泛防禦機制，尤其是在成人和老年人群中。為了支持這種廣譜保護潛力，南丹麥大學於2024年10月進行的一項研究發現，卡介苗接種可使75歲以下人群急性感染疾病的發生率降低0.82倍，這表明該疫苗有望成為增強老年人免疫力的預防工具。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球卡介苗市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品（免疫用卡介苗、治療用卡介苗）
    • 透過應用（結核病、膀胱癌）
    • 分銷管道（醫院、診所等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美卡介苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲卡介苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區卡介苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲卡介苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲卡介苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球卡介苗市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Serum Institute of India Pvt. Ltd.
  • GreenSignal Bio Pharma Ltd
  • Taj Pharmaceuticals Limited
  • Japan BCG Laboratory
  • Merck & Co., Inc.
  • Microgen LLC
  • Biomed Lublin SA
  • BCG Vaccine Laboratory
  • China Biotechnology Co., Ltd.
  • AJ Biologics Sdn Bhd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18763

The Global BCG Vaccines Market is projected to expand robustly, growing from USD 149.71 Million in 2025 to USD 212.01 Million by 2031, at a compound annual growth rate of 5.97%. The Bacillus Calmette-Guerin (BCG) vaccine, a live attenuated formulation derived from Mycobacterium bovis, is primarily administered to neonates for tuberculosis protection and is also utilized as an intravesical immunotherapy for early-stage bladder cancer. The market's stability is largely underpinned by the strict enforcement of national immunization mandates in high-burden regions and the consistent clinical application of BCG in oncological treatment protocols. These fundamental drivers ensure predictable procurement volumes, establishing a baseline of demand that operates independently of emerging technological advancements in vaccine delivery. However, a significant impediment to market expansion is the inherent fragility of the global supply chain, characterized by a high concentration of production among a limited number of pre-qualified manufacturers. This consolidation makes the market susceptible to shortages and complicates logistics, particularly for low-income nations reliant on uninterrupted access. UNICEF data from 2024 indicates a global estimated demand of approximately 330 million BCG vaccine doses, underscoring the immense pressure on existing manufacturing infrastructures to sustain adequate public health coverage.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 149.71 Million
Market Size 2031USD 212.01 Million
CAGR 2026-20315.97%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Market Driver

The escalating global prevalence of tuberculosis in high-burden regions serves as the primary volume driver for the market, necessitating continuous procurement for effective disease control. As infection rates climb, national health systems face increasing pressure to broaden immunization coverage and therapeutic interventions to mitigate transmission. According to the World Health Organization's 'Global Tuberculosis Report 2024', approximately 8.2 million new tuberculosis diagnoses were recorded in 2023, representing the highest number since global monitoring began. This record burden reinforces the critical need for resilient vaccine supply chains to achieve public health objectives, particularly in developing economies, with UNICEF reporting an estimated weighted average price of $0.18 per dose for the BCG vaccine in 2024, balancing affordability with production costs. Concurrently, the increasing adoption of BCG immunotherapy for non-muscle invasive bladder cancer significantly propels market value, creating a distinct high-revenue segment separate from pediatric immunization. While this oncological application commands consistent clinical reliance, the growing preference for this protocol exacerbates existing manufacturing constraints, resulting in notable availability gaps. The tension between rising clinical adoption and finite production capacity is evident in recent treatment disruptions, with a UroToday article from 2024 indicating that 21% of analyzed patients were directly impacted by BCG shortages, compelling providers to modify standard treatment regimens. This data highlights how supply scarcity remains a critical bottleneck restricting the full commercial potential of BCG in oncological settings.

Market Challenge

The principal challenge impeding the growth of the Global BCG Vaccines Market is the fragility of its global supply chain, primarily driven by the intense concentration of production among a limited number of manufacturers. This structural consolidation fosters a high-risk environment where operational disruptions, regulatory hurdles, or quality control failures at a single facility can trigger immediate, widespread shortages. Consequently, the market struggles to maintain the reliability essential for rigorous national immunization schedules, forcing procurement agencies to operate with minimal buffer stocks. This instability undermines buyer confidence and restricts the market's ability to expand supply for secondary applications, such as bladder cancer immunotherapy, as core pediatric needs must be prioritized during deficits. The severity of this monopolistic reliance is starkly illustrated by UNICEF's 2024 assessment, which reported that a single Indian manufacturer accounted for approximately 70% of the overall production capacity from WHO pre-qualified suppliers. Such a skewed dependency ratio signifies that the market lacks the diversification necessary to effectively absorb supply shocks, with the resulting lack of redundancy creating severe logistical bottlenecks that directly impede steady market expansion and revenue predictability.

Market Trends

The integration of BCG into combination bladder cancer therapies represents a pivotal shift in oncological treatment protocols, specifically addressing the significant clinical challenge of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). By combining intravesical BCG with novel immunomodulators, such as IL-15 superagonist complexes, pharmaceutical developers are enhancing the therapeutic efficacy of the standard-of-care regimen without abandoning BCG's foundational role. This approach revitalizes the market by extending the vaccine's utility in high-risk patient populations who might otherwise face radical cystectomy. Demonstrating this clinical advancement, ImmunityBio's April 2024 press release reported that the combination of ANKTIVA with BCG achieved a complete response rate of 62% in patients with BCG-unresponsive NMIBC, establishing a new benchmark for durable therapeutic outcomes. Concurrently, the rising focus on trained immunity research is expanding the commercial horizon of the vaccine beyond its traditional pediatric tuberculosis indication, investigating its capacity to confer non-specific protection against diverse respiratory pathogens and neurodegenerative conditions. This scientific trend leverages BCG's ability to induce epigenetic reprogramming in innate immune cells, thereby enhancing the host's broad-spectrum defense mechanisms, particularly in adult and elderly demographics. Validating this broader protective potential, a University of Southern Denmark study in October 2024 found that BCG vaccination reduced the incidence of acute infections in participants aged under 75 years by a hazard ratio of 0.82, suggesting a viable pathway for repositioning the vaccine as a prophylactic tool for geriatric immune resilience.

Key Market Players

  • Serum Institute of India Pvt. Ltd.
  • GreenSignal Bio Pharma Ltd
  • Taj Pharmaceuticals Limited
  • Japan BCG Laboratory
  • Merck & Co., Inc.
  • Microgen LLC
  • Biomed Lublin S.A.
  • BCG Vaccine Laboratory
  • China Biotechnology Co., Ltd.
  • AJ Biologics Sdn Bhd

Report Scope

In this report, the Global BCG Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

BCG Vaccines Market, By Product

  • Immune BCG
  • Therapy BCG

BCG Vaccines Market, By Application

  • Tuberculosis
  • Bladder Cancer

BCG Vaccines Market, By Distribution Channel

  • Hospitals
  • Clinics
  • Others

BCG Vaccines Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global BCG Vaccines Market.

Available Customizations:

Global BCG Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global BCG Vaccines Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Immune BCG, Therapy BCG)
    • 5.2.2. By Application (Tuberculosis, Bladder Cancer)
    • 5.2.3. By Distribution Channel (Hospitals, Clinics, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America BCG Vaccines Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States BCG Vaccines Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada BCG Vaccines Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico BCG Vaccines Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Distribution Channel

7. Europe BCG Vaccines Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany BCG Vaccines Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France BCG Vaccines Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom BCG Vaccines Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy BCG Vaccines Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain BCG Vaccines Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific BCG Vaccines Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China BCG Vaccines Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India BCG Vaccines Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan BCG Vaccines Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea BCG Vaccines Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia BCG Vaccines Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa BCG Vaccines Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia BCG Vaccines Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE BCG Vaccines Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa BCG Vaccines Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. South America BCG Vaccines Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil BCG Vaccines Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia BCG Vaccines Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina BCG Vaccines Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global BCG Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Serum Institute of India Pvt. Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GreenSignal Bio Pharma Ltd
  • 15.3. Taj Pharmaceuticals Limited
  • 15.4. Japan BCG Laboratory
  • 15.5. Merck & Co., Inc.
  • 15.6. Microgen LLC
  • 15.7. Biomed Lublin S.A.
  • 15.8. BCG Vaccine Laboratory
  • 15.9. China Biotechnology Co., Ltd.
  • 15.10. AJ Biologics Sdn Bhd

16. Strategic Recommendations

17. About Us & Disclaimer